parkinson's Archives

parkinson’s

February 24, 2023

Evidence mounts linking air pollution to Parkinson’s disease

By Grace van Deelen

New research adds to evidence that people living in areas with high air pollution are at a higher risk of developing Parkinson’s disease, a progressive neurological disorder.

The research found a nationwide association between incidents of Parkinson’s and annual average particulate matter air pollution, also known as PM 2.5. Researchers found that at the highest annual exposure level, participants were 25% more likely to develop Parkinson’s disease, compared to those with the lowest exposure.

The findings are expected to be presented at the American Academy of Neurology’s meeting in April and published in the journal Neurology. The work was funded by grants from the US Department of Defense, the National Institutes of Health National Institute of Environmental Health Sciences, and the Michael J. Fox Foundation for Parkinson’s Research.

“It’s a very compelling story that we see,” said Brittany Krzyzanowski, a scientist at the Barrow Neurological Institute and lead author on the new study.

Researchers used data from over 22 million Americans, 83,674 of whom had reported a Parkinson’s diagnosis. They analyzed that data alongside geographical data showing the amount of PM 2.5 in the atmosphere. PM 2.5 is a type of air pollution that comes from vehicle exhaust, forest and grass fires, and other industrial processes, meaning that communities near highways and industrial areas are most likely to have high exposure.

The link between the disease and PM 2.5 has been suggested in numerous other studies, including a 2022 review of existing research that found air pollution to be “an emerging risk factor in the development of Parkinson’s disease.”

As well, a 2018 study of more than 2 million Ontario adults found that long-term exposure to PM 2.5 was associated with a 4% increase in instances of Parkinson’s, while a 2020 study of 63 million US adults found an association between PM 2.5 exposure and hospitalization for Parkinson’s.

October 21, 2022

A human toll- paraquat users blame Syngenta for Parkinson’s disease

By Carey Gillam and Aliya Uteuova

When Illinois farmer Ron Niebruegge was diagnosed with Parkinson’s disease at the age of 55, he was certain it must be a mistake. Niebruegge had always been healthy and active, someone who loved horseback riding and taking his wife dancing on weekend nights.

But a dizzy spell and a fall in 2007 led him to visit a neurologist, and then another. Both doctors agreed that the little things Niebruegge had started to notice – a left arm that didn’t seem to work quite right, some stiffness in his joints – were undeniable signs of the onset of Parkinson’s, a progressive debilitating brain disease for which there is no cure.

Now 70 years old, Niebruegge lives a very different life: The horses he loved have been given away and the horse trailer sold. Dancing is a thing of the past; Niebruegge struggles simply to walk across a room. He uses a cane but falls so frequently and unexpectedly that he fears leaving home.

One recent fall left him with a dislocated shoulder that required surgery. And his wife of 49 years has transitioned from dance partner to caregiver.

Niebruegge is far from alone. More than 8 million people globally suffer from what scientists see as the fastest growing neurological disorder in the world. And while scientists see multiple toxins as potential causes, one pesticide popular with farmers across the US has been prominently linked to the disease: a weed killer called paraquat that has grown in use over recent decades.

The longtime manufacturer of paraquat, Syngenta AG, along with Chevron USA, the successor to a former US paraquat distributor, are now being sued by thousands of Parkinson’s sufferers. The plaintiffs claim scientific studies show that exposure to paraquat can cause, or significantly increase the risk of, Parkinson’s disease, but rather than warn users, the companies prioritized paraquat sales over human health.